PubMed Health⌕ Search

Biomedical subjects

G Needham

Publications and source records attributed to G Needham.

40 records · Page 3Linked to original sources

Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.

The endocrine effects of aminoglutethimide 125 mg twice daily and hydrocortisone 20 mg twice daily were assessed in 45 postmenopausal women with advanced breast cancer. Oestrone and oestradiol levels were suppressed by 60% within 2 weeks and suppression was maintained for more than 6 months of chronic treatment. In contrast to conventional dose AG with hydrocortisone, or low dose AG without hydrocortisone, delta 4 androstenedione was suppressed by 65%. This effect may contribute to optimal oestrogen suppression.

Aminoglutethimide↗

Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer.

Aminoglutethimide 125 mg twice daily and hydrocortisone 20 mg twice daily was used to treat 76 postmenopausal women with advanced breast cancer. There were 4 CR, 17 PR (objective response rate 28%). Highest response was in soft tissue. CNS toxicity was less than with conventional dose AG (drowsiness 7% v. 31%), although the incidence of rash was equivalent. Previous responders to tamoxifen had a higher response (33%) than previous non-responders (9%). The lower toxicity and maintained efficacy suggest that this should be the standard dosage regimen.

Aged↗

Urokinase receptors in lung cancer and normal lung.

Cell membranes from ten non-small cell lung cancers and four specimens of adjacent lung tissue were assessed for the presence of urokinase type plasminogen activator (uPA) receptors. Displacement binding studies using 125I labelled urokinase showed specific binding on lung cancer and lung membrane preparations. Scatchard analysis showed that the dissociation constant of high affinity sites on tumour membranes was 2.9 x 10(-11) M/1 and on lung membranes was 2 x 10(-9) M/1. The concentration of high affinity binding sites on tumour membrane was 54 fmol/mg of membrane protein and on normal lung membrane was 170 fmol/mg protein. Two-point binding assays showed specific binding of urokinase on five of eight tumour membranes and one of three normal lung membranes. There was no correlation between the amount of urokinase bound and tumour subtype or extent of disease. Because of interactions between uPA and epidermal growth factor receptors (EGFr) in cell culture and because lung cancers express increased EGFr we studied the association of uPA receptors and EGFr. Seven tumours expressed EGFr at 6.8-67.6 fmol/mg of protein of EGFr and four normal lung membranes had EGFr at 5.2-15.6 fmol/mg protein EGFr. There was no correlation between uPA receptors and EGFr in this series. We conclude that non-small cell lung cancers carry receptors for urokinase and this provides a novel mechanism for control of local proteolysis.

Adenocarcinoma↗